Does Medicare Cover Ozempic? The 2026 Rules Explained

You searched "does Medicare cover Ozempic" because a pharmacist, a friend, or a denial letter told you something that did not match what you thought. The answer is yes and no, and it hinges on one word on your prescription: diabetes.

Here is what it means. Part D can only cover a drug when it is prescribed for an FDA-approved indication not on the statutory exclusion list. Ozempic is FDA-approved for two things — type 2 diabetes and reducing cardiovascular events in adults with T2D — and nothing else.[1] Weight loss is on the exclusion list. So if your doctor writes Ozempic for anything other than diabetes, Medicare is not allowed to pay. This guide walks through the five questions seniors actually ask: what is covered, what it costs, what is changing in 2026–2027, what to do if denied, and how Medicare Advantage differs.

Is Ozempic Covered by Medicare?

For type 2 diabetes, yes. Ozempic is on virtually every national Part D formulary, including Aetna, UHC, Cigna, Humana, and BCBS plans. Your plan will require prior authorization — diagnosis codes, a recent A1c, usually a prior trial of metformin — but approval is routine when paperwork is complete.[1]

For weight loss, no. The 2003 Medicare Modernization Act, which created Part D, excludes "agents when used for anorexia, weight loss, or weight gain" from covered drugs.[10] This is not a decision by your plan — it is federal law binding every Part D plan. A 2024 administration proposal to reinterpret that exclusion for anti-obesity medications was not finalized; the statute still governs in 2026.[3]

This creates the most common senior denial scenario: a doctor writes Ozempic for weight loss or pre-diabetes, and Part D rejects it. The denial is technically correct. The fix is usually not an appeal on the same indication — it is a clinical conversation about whether you have documented T2D (A1c ≥ 6.5%) or a different drug with an obesity indication might be appropriate.

How Much Does Ozempic Cost on Medicare?

For a Medicare beneficiary with T2D who clears prior authorization, Ozempic lands on the preferred or non-preferred brand tier of most formularies. Monthly out-of-pocket typically runs $45 to $200 before the annual cap, depending on tier and whether you qualify for Low-Income Subsidy (LIS / Extra Help).[3] Starting in 2026, Part D caps total annual out-of-pocket spending at $2,100 across all drugs combined — even a worst-case high-tier copay stops adding up past that ceiling.[3]

A few things are not true for Medicare that are true elsewhere:

• The NovoCare $25 copay card does not work with Medicare. Federal anti-kickback rules bar manufacturer copay cards on government drug benefits; the card is only for commercial insurance.[12]
• GoodRx coupons do not stack with Medicare. You can use a GoodRx coupon instead of Medicare to self-pay Ozempic at retail, but you cannot combine it with Part D cost-sharing.[13]
• The Medicare $50/month flat copay is only for the Bridge program, which starts July 2026 and covers Wegovy and Zepbound, not Ozempic.[4]

If you do not have diabetes and your doctor writes Ozempic anyway, you are looking at full cash pay: about $997 list price, with GoodRx reporting average retail around $1,387.[13] A Costco price or the $199 introductory self-pay offer from Novo Nordisk (through June 2026) are the lowest realistic cash paths — but you are paying out of pocket, not through Medicare.

What's Changing: Wegovy, the Bridge, and the BALANCE Model

Medicare policy on GLP-1s is in the middle of the biggest change since Part D launched. Three things are moving at once.

1. Wegovy got a cardiovascular indication in 2024. Because Wegovy is now approved to reduce heart attack and stroke risk in adults with overweight or obesity plus established cardiovascular disease, Part D plans are allowed to cover Wegovy when written for that CV indication.[2][10] The prescription must be for CV risk reduction, not weight loss — but it is the first crack in the Medicare wall beyond T2D.[8]

2. The Medicare GLP-1 Bridge launches July 2026. Under the Bridge, participating manufacturers supply eligible GLP-1 drugs at a net price of $245/month, and Medicare beneficiaries pay a flat $50 copay regardless of plan tier.[4] It covers Wegovy and Zepbound — the two obesity-indicated GLP-1s. Ozempic, Mounjaro, and Rybelsus are not included because they are diabetes drugs.

3. The BALANCE Model launches January 2027. This is the full Part D benefit for obesity drugs. State Medicaid can opt in starting May 2026; standalone Part D and MA-PD plans join January 2027. CMS negotiates prices with manufacturers directly.[5]

What to Do if You Do Not Have Diabetes

This is the hardest bucket: a Medicare beneficiary with obesity, or obesity plus cardiovascular risk, who wants an effective GLP-1. Here are four real options, in rough order of how many people they apply to.

Medicare Advantage vs. Standalone Part D — Does It Matter?

Yes, but probably less than you think. Medicare Advantage (MA) plans bundle Part D drug coverage with medical benefits and are bound by the same federal rules: Ozempic covered for T2D, not weight loss. The differences are not about whether Ozempic is covered — they are about tier, PA form length, and step therapy.

Peterson-KFF's 2025 analysis found more than 98% of plans require prior authorization for GLP-1s and step therapy appears on fewer than 25% of plans.[10] Your MA plan will cover Ozempic for diabetes, but the PA form and tier copay will differ from a standalone Part D plan. UnitedHealthcare's Wegovy PA policy effective February 2026, for example, requires documented BMI plus a weight-related comorbidity and grants a 12-month authorization window — a template close to what most MA plans use.[14]

During open enrollment (October 15–December 7), use Medicare.gov Plan Compare to filter plans by the GLP-1 you need. It returns each plan's tier, restrictions, and estimated annual cost based on your dose. If you anticipate switching to Wegovy under the Bridge in July 2026, pick a plan that already lists Wegovy on formulary for the CV indication — it simplifies the transition.

The bottom line: for someone with type 2 diabetes, Medicare works, Ozempic is covered, and the main task is clearing prior authorization. For someone without diabetes who wants Ozempic for weight loss, Medicare will not cover it — because Ozempic is not FDA-approved for that use. The path forward is Wegovy through the Bridge in July 2026, a Wegovy CV prescription today if you qualify, or an appeal with documented obesity comorbidity. The rules are not fair to everyone, but they are knowable, and the timeline is finally moving.